Nicola Simola1, Giulia Costa2, Micaela Morelli2,3. 1. Department of Biomedical Sciences, Section of Neuropsychopharmacology, University of Cagliari, Via Ospedale, 72, 09124, Cagliari, Italy. nicola.simola@gmail.com. 2. Department of Biomedical Sciences, Section of Neuropsychopharmacology, University of Cagliari, Via Ospedale, 72, 09124, Cagliari, Italy. 3. CNR, National Research Council of Italy, Neuroscience Institute, Cagliari, Italy.
Abstract
RATIONALE: Rats emit 50-kHz ultrasonic vocalizations (USVs) in response to pleasurable stimuli, and these USVs are considered a tool for investigating reward and motivation. OBJECTIVES: This study aimed to clarify how activity of adenosine A2A receptors, which modulate reward and motivation, influences 50-kHz USV emission in rats. METHODS: Rats received one of the following treatments in a test cage: (1) acute administration of the A2A receptor agonist CGS 21680 (0.05-0.2 mg/kg, i.p.) during social interactions; (2) long-term amphetamine (1 or 2 mg/kg, i.p.) or morphine (7.5 mg/kg, s.c.) administration on alternate days, alone or with CGS 21680, followed after 7 days of discontinuation by test cage re-exposure, to assess drug-conditioning effects, and thereafter drug challenge; (3) acute administration of the D1/D2 receptor agonist apomorphine (4 mg/kg, i.p.), alone or with CGS 21680; and (4) long-term administration of the non-selective A1/A2A receptor antagonist caffeine (15 mg/kg, i.p.), on alternate days. USVs and locomotor activity were evaluated throughout the treatments. RESULTS: CGS 21680 attenuated 50-kHz USV emission stimulated by social interactions, amphetamine, apomorphine, and morphine, and rats administered CGS 21680 with amphetamine or morphine emitted fewer conditioned 50-kHz USVs upon test cage re-exposure, compared with rats administered amphetamine or morphine alone. Moreover, CGS 21680 administration prevented long-term changes in locomotor activity in amphetamine- and morphine-treated rats. Finally, caffeine had no effect on 50-kHz USVs. CONCLUSIONS: These results indicate that activation of A2A receptors attenuates 50-kHz USV emission in rats and further elucidate how these receptors modulate the motivational properties of natural and pharmacological stimuli.
RATIONALE: Rats emit 50-kHz ultrasonic vocalizations (USVs) in response to pleasurable stimuli, and these USVs are considered a tool for investigating reward and motivation. OBJECTIVES: This study aimed to clarify how activity of adenosine A2A receptors, which modulate reward and motivation, influences 50-kHz USV emission in rats. METHODS:Rats received one of the following treatments in a test cage: (1) acute administration of the A2A receptor agonist CGS 21680 (0.05-0.2 mg/kg, i.p.) during social interactions; (2) long-term amphetamine (1 or 2 mg/kg, i.p.) or morphine (7.5 mg/kg, s.c.) administration on alternate days, alone or with CGS 21680, followed after 7 days of discontinuation by test cage re-exposure, to assess drug-conditioning effects, and thereafter drug challenge; (3) acute administration of the D1/D2 receptor agonist apomorphine (4 mg/kg, i.p.), alone or with CGS 21680; and (4) long-term administration of the non-selective A1/A2A receptor antagonist caffeine (15 mg/kg, i.p.), on alternate days. USVs and locomotor activity were evaluated throughout the treatments. RESULTS:CGS 21680 attenuated 50-kHz USV emission stimulated by social interactions, amphetamine, apomorphine, and morphine, and rats administered CGS 21680 with amphetamine or morphine emitted fewer conditioned 50-kHz USVs upon test cage re-exposure, compared with rats administered amphetamine or morphine alone. Moreover, CGS 21680 administration prevented long-term changes in locomotor activity in amphetamine- and morphine-treated rats. Finally, caffeine had no effect on 50-kHz USVs. CONCLUSIONS: These results indicate that activation of A2A receptors attenuates 50-kHz USV emission in rats and further elucidate how these receptors modulate the motivational properties of natural and pharmacological stimuli.
Authors: Charles W Schindler; Marzena Karcz-Kubicha; Eric B Thorndike; Christa E Müller; Srihari R Tella; Sergi Ferré; Steven R Goldberg Journal: Br J Pharmacol Date: 2005-03 Impact factor: 8.739
Authors: Markus Wöhr; Henrike Rippberger; Rainer K W Schwarting; Marcel M van Gaalen Journal: Psychopharmacology (Berl) Date: 2014-11-25 Impact factor: 4.530
Authors: Allison M Mott; Eric J Nunes; Lyndsey E Collins; Russell G Port; Kelly S Sink; Jörg Hockemeyer; Christa E Müller; John D Salamone Journal: Psychopharmacology (Berl) Date: 2009-01-09 Impact factor: 4.530
Authors: Nitish Mittal; Neha Thakore; James M Reno; Richard L Bell; W Todd Maddox; Timothy Schallert; Christine L Duvauchelle Journal: Alcohol Date: 2017-09-14 Impact factor: 2.405
Authors: Steven J Simmons; Ryan A Gregg; Fionya H Tran; Lili Mo; Eva von Weltin; David J Barker; Taylor A Gentile; Lucas R Watterson; Scott M Rawls; John W Muschamp Journal: Addict Biol Date: 2016-12-01 Impact factor: 4.280